Expert consensus from the Chinese medical association on pharmaceutical management of combined cardio-oncology physician-pharmacist clinics - Scorecard - MDSpire
Advertisement
Expert consensus from the Chinese medical association on pharmaceutical management of combined cardio-oncology physician-pharmacist clinics
Clinical Scorecard: Guidelines from the Chinese Medical Association on the Pharmaceutical Management in Integrated Cardio-Oncology Clinics Involving Physicians and Pharmacists
At a Glance
Category
Detail
Condition
Cardio-Oncology
Key Mechanisms
Cardiotoxicity from anticancer drugs, including myocardial injury from anthracyclines and immune-mediated myocarditis from immune checkpoint inhibitors.
Target Population
Cancer patients with pre-existing cardiovascular conditions or those undergoing anticancer therapies.
Care Setting
Integrated cardio-oncology clinics involving physicians and pharmacists.
Key Highlights
Emergence of cardio-oncology as a response to cancer-related cardiovascular diseases.
Pharmacist-led clinics are being established to enhance medication management.
The Consensus aims to standardize management and improve pharmacotherapy safety and effectiveness.
Guideline-Based Recommendations
Diagnosis
Establish diagnostic workflows for cardio-oncology clinics.
Management
Implement pharmacist-led clinics for medication counseling and guidance.
Monitoring & Follow-up
Regular assessment of cardiovascular health in cancer patients.
Risks
Monitor for cardiotoxicity associated with anticancer therapies.
Patient & Prescribing Data
Cancer patients at risk of cardiovascular complications.
Focus on rational drug utilization and management of cardiotoxicity.
Clinical Best Practices
Utilize interdisciplinary approaches in managing cancer patients with cardiovascular issues.
Adhere to established guidelines and consensus for cardio-oncology management.
